Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

128.38 -0.25 (-0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,025,397
Open	128.02
Bid (Size)	118.19 (100)
Ask (Size)	135.00 (100)
Prev. Close	128.63
Today's Range	126.59 - 128.79
52wk Range	84.23 - 160.18
Shares Outstanding	100,100,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Performance

YTD	-8.7%	-8.7%
1 Month	-4.6%	-4.6%
3 Month	-9.1%	-9.1%
6 Month	-4.2%	-4.2%
1 Year	+7.8%	+7.8%

More News

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

Via The Motley Fool

Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗

February 17, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗

February 13, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗

February 11, 2026

Via Chartmill

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

Via The Motley Fool

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

Via The Motley Fool

Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Via The Motley Fool

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

January 31, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗

January 23, 2026

Via Chartmill

Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗

January 07, 2026

Via Chartmill

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗

January 05, 2026

Via Stocktwits

Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗

December 16, 2025

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗

December 04, 2025

Via Chartmill

Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗

December 03, 2025

Via The Motley Fool

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Via The Motley Fool

Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

Via The Motley Fool

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

Via The Motley Fool

High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗

November 13, 2025

Via Chartmill

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile ↗

November 11, 2025

Via Benzinga

Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 11, 2025

Via Benzinga

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?

Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?

Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?

The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market

What is the current price of Neurocrine Biosciences, Inc. - Common Stock?

The current price of Neurocrine Biosciences, Inc. - Common Stock is 128.38

When was Neurocrine Biosciences, Inc. - Common Stock last traded?

The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 02/23/26 04:00 PM ET

What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?

The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 12.85B

How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?

Neurocrine Biosciences, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.